Today: 30 December 2025
Subscribe
Browse Category

Pharma News News 4 December 2025 - 12 December 2025

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward
12 December 2025
 ·  ·  ·  · 
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and
12 December 2025
 ·  ·  ·  · 
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise
11 December 2025
 ·  ·  ·  · 
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh
11 December 2025
 ·  ·  ·  ·  · 
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and
7 December 2025
 ·  ·  ·  · 
1 2 3 4 5 … 7
Go toTop